Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study

Bimatoprost 0.03% has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects.

“Bimatoprost 0.03 % has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects.”

In both the Japanese study and the North American cohort, GEA score improvements were significantly correlated with greater patient-reported satisfaction with eyelashes.

“Moreover, in both populations, the GEA score improvements were significantly correlated with greater patient-reported satisfaction with eyelashes, as measured with ESQ-9 in the current study and with the original 23-item ESQ in the North American study [15].”

In both the Japanese study 1 and the North American cohort, improvement in eyelash prominence was maintained at the post-treatment assessment at month 5.

“In both populations, the improvement in eyelash prominence was maintained at the post-treatment assessment at month 5.”

The types of adverse events reported in the current trials were consistent with those of prior studies investigating mostly Caucasian populations with hypotrichosis of the eyelashes.

“The types of AEs reported in the current trials were consistent with those of prior studies investigating mostly Caucasian populations with hypotrichosis of the eyelashes [15, 17].”

The rate of conjunctival hyperemia reported at biomicroscopy was consistent with that previously reported in a mostly Caucasian cohort from a prior study.

“The rate of conjunctival hyperemia reported at biomicroscopy was consistent with that previously reported in a mostly Caucasian cohort from a prior study [15].”

Both the GEA and the GEA-J scales have been validated in previous clinical studies.

“Both the GEA and the GEA-J scales have been validated in previous clinical studies [15].”

In the North American study, statistically significant between-group differences in intraocular pressure were reported from week 1 through week 16, and by week 20 these differences had resolved.

“Statistically significant between-group differences in IOP were reported in the North American study from week 1 through week 16. By the week 20 visit, these differences had resolved [15].”